R-5280 in Newly Diagnosed Patients With Type 1 Diabetes

Completed · Phase 1 · Has a placebo group

Conditions studied: Type 1 Diabetes, Type 1 Diabetes (Juvenile Onset), Diabetes Mellitus, Type 1

In brief

Evaluating the adverse events and tolerance of R-5280 in Mitigating Type 1 Diabetes in Newly Diagnosed Patients

Key facts

Study ID
NCT06057454
Run by
Rise Therapeutics LLC
People needed
9
Starts
2023-12-05
Expected to finish
2025-11-05
Last updated by the study team
2025-11-10

Who can join

Age: 11 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.